Inhibition of cell migration and invasion mediated by the TAT-RasGAP317-326 peptide requires the DLC1 tumor
D Barras1, G Lorusso2, C Rüegg2
1Department of Physiology, University of Lausanne, Lausanne, Switzerland.
Abstract:
TAT-RasGAP(317-326), a peptide corresponding to the 317-326 sequence of p120 RasGAP coupled with a cell-permeable TAT-derived peptide, sensitizes the death response of various tumor cells to several anticancer treatments. We now report that this peptide is also able to increase cell adherence, prevent cell migration and inhibit matrix invasion. This is accompanied by a marked modification of the actin cytoskeleton and focal adhesion redistribution. Interestingly, integrins and the small Rho GTP-binding protein, which are well-characterized proteins modulating actin fibers, adhesion and migration, do not appear to be required for the pro-adhesive properties of TAT-RasGAP(317-326). In contrast, deleted in liver cancer-1, a tumor suppressor protein, the expression of which is often deregulated in cancer cells, was found to be required for TAT-RasGAP(317-326) to promote cell adherence and inhibit migration. These results show that TAT-RasGAP(317-326), besides its ability to favor tumor cell death, hampers cell migration and invasion.
Insights
The peptide TAT-RasGAP(317-326) enhances tumor cell death and also inhibits cancer cell migration and invasion. This peptide alters the actin cytoskeleton and focal adhesions, offering a dual-action therapeutic strategy.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- The peptide TAT-RasGAP(317-326) is derived from p120 RasGAP and a cell-penetrating TAT peptide.
- It is known to sensitize tumor cells to anticancer treatments, promoting cell death.
Purpose of the Study:
- To investigate the effects of TAT-RasGAP(317-326) on cancer cell adhesion, migration, and invasion.
- To elucidate the molecular mechanisms underlying these effects, particularly the role of cytoskeletal and adhesion proteins.
Main Methods:
- Treatment of various tumor cells with TAT-RasGAP(317-326).
- Assessment of cell adherence, migration, and invasion assays.
- Analysis of actin cytoskeleton and focal adhesion dynamics.
- Investigation of the involvement of integrins, Rho GTP-binding proteins, and deleted in liver cancer-1 (DLC1).
Main Results:
- TAT-RasGAP(317-326) significantly increased cell adherence.
- The peptide inhibited cell migration and matrix invasion.
- These effects were associated with modifications in the actin cytoskeleton and focal adhesion distribution.
- Pro-adhesive effects were independent of integrins and Rho GTP-binding proteins.
- The tumor suppressor DLC1 was found to be essential for the pro-adhesive and anti-migratory actions of TAT-RasGAP(317-326).
Conclusions:
- TAT-RasGAP(317-326) possesses dual functions: promoting tumor cell death and inhibiting cancer cell migration and invasion.
- The peptide's anti-migratory and pro-adhesive effects are mediated through DLC1, independent of classical integrin and Rho GTPase pathways.
- These findings highlight TAT-RasGAP(317-326) as a promising agent for cancer therapy with multifaceted mechanisms of action.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
Cancer Cell Migration through Invadopodia
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Abnormal Proliferation


